Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2017 (2017), Article ID 8560827, 8 pages
https://doi.org/10.1155/2017/8560827
Research Article

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis

1Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA
2University of Kentucky College of Medicine, Lexington, KY, USA
3Departments of Oncology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Correspondence should be addressed to Chun Li; ude.esac@197lxc

Received 10 August 2017; Accepted 26 October 2017; Published 21 November 2017

Academic Editor: William L. Dahut

Copyright © 2017 Mike Fang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplemental 1, Figure: Funnel plots showing the effect against precision for all treatment sequences for OS/PFS.

Supplemental 2/3, Figure: Pearson correlations between median OS/PFS and other variables shown on the lower left with corresponding pairwise plots on the upper right. Distributions of each variable are displayed along the diagonal. Plotting PSA decline, Gleason score, and baseline PSA against median OS/PFS indicate trends that are consistent with expected clinical outcomes.

Supplemental 4/5, Appendix: Results of regression models for median OS/PFS as outcomes. Hash marks indicate the specific model.

  1. Supplementary Material